RE:AstraZeneca's ADC disappoints - on severe adverse eventsMarch 06, 2024 - Rapid Relapse of PD-L1–Negative TNBC After Neoadjuvant Therapy and antibody drug conjugate (ADC) Sacituzumab Govitecan - the next steps are not as clear
Sacituzumab govitecan, a TOP1 inhibitor antibody-drug conjugate (ADC) against Trop-2, emerged as a next line of therapy for patients who have developed metastatic disease after prior chemotherapy. For patients whose disease progresses after this, however, the next steps are not as clear, according to Melissa Yacur, MD, and Teja Poosarla, MD
https://dailynews.ascopubs.org/do/following-rapid-relapse-pd-l1-negative-tnbc-after-neoadjuvant-therapy-and-sacituzumab